Post-operative Radiotherapy In Minimum-risk Elderly - Phase II
ISRCTN | ISRCTN95889329 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN95889329 |
Secondary identifying numbers | CZH/4/296 |
- Submission date
- 17/06/2005
- Registration date
- 17/08/2005
- Last edited
- 16/02/2023
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English Summary
Contact information
Dr Ian Kunkler
Scientific
Scientific
Edinburgh Cancer Centre
Western General Hospital
Crewe Road
Edinburgh
EH4 2XU
United Kingdom
Phone | +44 (0)131 537 2214 |
---|---|
i.kunkler@ed.ac.uk |
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Not specified |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Post-operative Radiotherapy In Minimum-risk Elderly - Phase II |
Study acronym | PRIME II |
Study hypothesis | To assess the role of post-operative breast radiotherapy in women aged 65 or older, with low risk breast cancer treated by breast conserving surgery and adjuvant endocrine therapy: in particular to estimate the difference in local recurrence rates between patients treated with and without radiotherapy. This trial is related to PRIME I and details in http://www.controlled-trials.com/ISRCTN14817328 |
Ethics approval(s) | Not provided at time of registration |
Condition | Breast cancer |
Intervention | The control arm receive standard breast irradiation (40-50 Gy) over 3-6 weeks and the experimental group receive no breast irradiation. All eligible patients are to receive some form of endocrine therapy. |
Intervention type | Other |
Primary outcome measure | Ipsilateral breast cancer recurrence rates |
Secondary outcome measures | Regional recurrence, contralateral breast cancer, distant metastases, disease free survival and overall survival |
Overall study start date | 01/01/2003 |
Overall study end date | 30/11/2008 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Senior |
Sex | Female |
Target number of participants | 1000 |
Total final enrolment | 1326 |
Participant inclusion criteria | 1. Breast conserving surgery with a complete pathological excision margin of all invasive and non invasive cancer (a minimum of 1 mm on histological assessment) 2. Histologically confirmed unilateral breast cancer of pathological size 3 cm or less 3. Oestrogen receptor or progesterone receptor positive and treated with post-operative adjuvant endocrine therapy (patients who have been treated with pre-operative neo-adjuvant endocrine therapy can be included) 4. No axillary node involvement on histological assessment 5. Medically suitable to attend for all treatment and follow up 6. Able and willing to give informed consent |
Participant exclusion criteria | 1. Age younger than 65 years (date of issue of pathology results) 2. Grade III cancer combined with lymphatic/vascular invasion 3. Previous in situ or invasive carcinoma of either breast 4. Current or previous malignancy, within the past 5 years, other than non-melanomatous skin cancer or carcinoma in situ of cervix |
Recruitment start date | 01/01/2003 |
Recruitment end date | 30/11/2008 |
Locations
Countries of recruitment
- Scotland
- United Kingdom
Study participating centre
Edinburgh Cancer Centre
Edinburgh
EH4 2XU
United Kingdom
EH4 2XU
United Kingdom
Sponsor information
University of Edinburgh (UK)
University/education
University/education
Old College
South Bridge
Edinburgh
EH8 9YL
Scotland
United Kingdom
Phone | +44 (0)131 650 1000 |
---|---|
communications.office@ed.ac.uk | |
Website | http://www.ed.ac.uk/ |
https://ror.org/01nrxwf90 |
Funders
Funder type
Charity
Robertson Trust, Glasgow. Trial was allowed to use unspent funds from another trial to set up the initial stages of the trial.
No information available
Chief Scientist Office, Scottish Executive (ref CZH/4/296)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan | Not provided at time of registration |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Plain English results | No | Yes | |||
Results article | results | 01/03/2015 | Yes | No | |
Results article | 16/02/2023 | 16/02/2023 | Yes | No |
Editorial Notes
16/02/2023: Publication reference and total final enrolment added.
17/10/2018: Cancer Research UK lay results summary link added to Results (plain English)